ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting

    Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World

    John Kelsall1, Anna Jaroszynska2, Louis Bessette3, Raman Joshi4, Isabelle Fortin5, Jacqueline Stewart6, Keltie Anderson7, Emmanouil Rampakakis8, Eliofotisti Psaradellis9, Francois Nantel10, Karina Maslova11, Brendan Osborne12, Cathy Tkaczyk12 and Allen J Lehman11, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2Private practice, Burlington, ON, Canada, 3Rheumatology, CHUL de Quebec, Quebec, QC, Canada, 4William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, 5Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, 6Penticton Regional Hospital, Penticton, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8JSS Medical Research, St-Laurent, QC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 1019 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose:  Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
  • Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting

    Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases

    John McKinnon1, Junying Zhou2, Jenna Hudy1, Sara Hegab1 and Kathleen Maksimowicz-McKinnon3, 1Henry Ford Hospital, Detroit, MI, 2Infectious Diseases, Henry Ford Hospital, Detroit, MI, 3Rheumatology, Henry Ford Hospital, Detroit, MI

    Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
  • Abstract Number: 2575 • 2016 ACR/ARHP Annual Meeting

    The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis

    Laura Grace1, Marwan Bukhari2, Robert Lauder3, Lisa Bishop4,5 and Adam Taylor1, 1Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom, 3Biomedical & Life Sciences, Lancaster University, Lancaster, United Kingdom, 4Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom, 5University Hopsitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom

    Background/Purpose:  Rheumatoid arthritis (RA) is a disease of unknown etiology;with a pathogenesis that is due to a mixture of genetic, immunological and environmental factors. A…
  • Abstract Number: 1003 • 2016 ACR/ARHP Annual Meeting

    Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome

    Emeline Gaigneux1, Grégoire Cormier2, Oriane Merot3, Yves Maugars4 and Benoit Le Goff4, 1rheumatology unit, Nantes University Hospital, Nantes, France, 2rheumatology unit, Hospital, La roche sur Yon, France, 3rheumatology unit, Hospital, Saint Nazaire, France, 4Rheumatology, Nantes University Hospital, Nantes, France

    Background/Purpose:   The main goal of this study was to describe the US changes observed during the course of septic arthritis and their association with…
  • Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting

    Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)

    Jacques Morel1,2, Arnaud CONSTANTIN3, Gabriel Baron4, Emmanuelle Dernis5, Rene-Marc Flipo6,7, Stephanie Rist Bouillon8, Bernard Combe9, Jacques-Eric Gottenberg10, Thierry Schaeverbeke11,12, Martin Soubrier13, Olivier Vittecoq14, Maxime Dougados15, Alain Saraux16, Xavier Mariette17, Philippe Ravaud18 and Jean Sibilia19, 1Montpellier University Hospital, Montpellier, France, 2Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 3Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 4Hôpital Hôtel Dieu, Paris, France, 5Service de Rhumatologie, Centre Hospitalier, Le Mans, France, 6Rheumatology, Hopital R Salengro CHRU, Lille, France, 7Rheumatology, University Hospital, Lille, France, 8Rhumatologie, Hopital La Source, La Source, France, 9Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 10Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11Bordeaux University Hospital, Bordeaux, France, 12Rheumatology, CHU Bordeaux, Bordeaux, France, 13Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 14Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 15Paris Descartes University, Paris, France, 16Rheumatology, Brest University Medical School Hospital, Brest, France, 17Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, 18Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, 19Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
  • Abstract Number: 1193 • 2016 ACR/ARHP Annual Meeting

    Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis

    Khushboo Sheth1,2, Chia-Ling Kuo3, Dhruv Modi4 and Christopher Scola5, 1Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, 2Rheumatology, Stanford University, Palo Alto, CA, 3Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT, 4Internal Medicine, Jamaica Hospital and Medical Center, New York, NY, 5Rheumatology, Hartford Hospital, Hartford, CT

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients.…
  • Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting

    Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database

    Tatsuya Atsumi1, Yoshiaki Ando2, Yukiko Hayashi2, Shinichi Matsuda2, Riwa Tanaka2, Nobuhiro Takagi2 and Ayako Nakasone2, 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Chugai Pharmaceutical Co. Ltd., Tokyo, Japan

    Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
  • Abstract Number: 1195 • 2016 ACR/ARHP Annual Meeting

    Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study

    Patompong Ungprasert1, Cynthia S. Crowson2 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN

    Risk of Hospitalized Infection Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Increased risk of infection has been observed in several autoimmune disorders. …
  • Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting

    Safety of Multiple Retreatments with Rituximab  in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Alain Cantagrel4, Bernard Combe5, Maxime Dougados6, RENE MARC FLIPO7, Olivier Vittecoq8, Thierry Schaeverbeke9, Isabelle Pane10, Jean Sibilia11, Xavier Mariette12 and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hotel Dieu, PARIS, France, 3Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 9Rheumatology, CHU Bordeaux, Bordeaux, France, 10Epidemiology, Hotel Dieu, Paris, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…
  • Abstract Number: 1311 • 2016 ACR/ARHP Annual Meeting

    Causative Pathogens, Antibiotic Susceptibility, and Characteristics of Patients with Bacterial Septic Arthritis over Time

    Sadao Jinno1, Carol Sulis2 and Maureen Dubreuil3,4, 1Rheumatology, Boston University School of Medicine, Boston, MA, 2infectious disease, Boston University School of Medicine, Boston, MA, 3Rheumatology, Boston VA HealthCare System, Boston, MA, 4Clinical Epidemiology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Management of septic arthritis remains a challenge. The emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced vancomycin susceptibility and multi drug resistant (MDR)…
  • Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting

    Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent

    Shinji Motojima1, Tamao Nakashita2, Akira Jibatake1, Akira Yoshida1 and Yoshiki Yamamoto1, 1Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, 2Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan

    Background/Purpose:  Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…
  • Abstract Number: 1313 • 2016 ACR/ARHP Annual Meeting

    Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience

    Muhsen Al-ani1, Yasir Abdulqader1, Robert Myers1, Napatkamon Ayutyanont‎2, Bikash Bhattarai2 and Konstantinos Parperis3, 1Internal Medicine, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ, 2Research, Maricopa Integrated Health System, phoenix, AZ, 3Rheumatology, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ

    Background/Purpose:  HIV infection has been associated with a plethora of rheumatologic diseases, however there are only few studies in the US analyzing the frequency of…
  • Abstract Number: 3116 • 2016 ACR/ARHP Annual Meeting

    Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry

    Gabriella Giancane1, Joost Swart2, Francesca Bovis2, Elio Castagnola2, Andreas Groll2, Gerd Horneff2, Hans-Iko Huppertz2, Daniel J. Lovell2, Tom Wolfs2, Michaël Hofer2, Ekaterina Alexeeva2, Violeta Vladislava Panaviene2, Susan Nielsen2, Jordi Anton2, Florence Uettwiller2, Valda Stanevicha2, Maria Trachana2, Denise Pires Marafon3, Constantin Ailioaie2, Elena Tsitsami2, Sylvia S.M. Kamphuis2, Troels Herlin2, Pavla Dolezalová3, Gordana Susic2, Berit Flato2, Flavio Sztajnbok2, Angela Pistorio1, Alberto Martini2, Nico Wulffraat2 and Nicolino Ruperto2, 1Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, 2Istituto Giannina Gaslini, Genoa, Italy, 3Istituto Giannina Gaslini, genoa, Italy

    Background/Purpose: Pharmachild is an international registry involving over 100 the Paediatric Rheumatology INternational Trials Organisation (PRINTO)/ the Paediatric Rheumatology European Society (PRES) centres in 38 countries. The registry was set up to evaluate long term safety and efficacy…
  • Abstract Number: 1316 • 2016 ACR/ARHP Annual Meeting

    Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect

    Mary Louise Fowler1, Sarah B. Lieber2, Andy Moore3, Robert Shmerling4 and Ziv Paz2, 1Boston University School of Medicine, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, 4Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: In developed countries, certain health outcomes are worse among men. For example, in the US, life expectancy for men is 5 years shorter than…
  • Abstract Number: 1317 • 2016 ACR/ARHP Annual Meeting

    Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?

    Mary Louise Fowler1, Kevin Byrne1, Sarah B. Lieber2, Andy Moore3, Robert Shmerling4 and Ziv Paz2, 1Boston University School of Medicine, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, 4Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA

    Do patients with MRSA-positive septic arthritis differ clinically from non-MRSA-positive counterparts? Mary Louise Fowler3, Kevin Byrne3, Sarah B. Lieber1, Andrew Moore2, Robert H. Shmerling1, Ziv…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology